SCHEMBL6416768

SCHEMBL6416768

Cc1ccc2c(c1)C(C(=O)NC1=NCCS1)C(c1cc(C(F)(F)F)cc(C(F)(F)F)c1)N(C)C2=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.41
USP2 O75604 4/20 0.41
ALDH1A1 P00352 4/20 0.38
RAB9A P51151 3/20 0.38
KDM4E B2RXH2 2/20 0.38
TSHR P16473 3/20 0.38
MAPK1 P28482 2/20 0.38
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
NFKB1 P19838 1/20 0.37
NFKB2 Q00653 1/20 0.37
RELA Q04206 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
ALOX15 P16050 1/20 0.36
HSD17B10 Q99714 2/20 0.35
LMNA P02545 1/20 0.35
POLB P06746 1/20 0.35
MAPT P10636 1/20 0.35
CYP1A2 P05177 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6418393 0.90 TSHR (0.45) NPC1USP2ALDH1A1KDM4ETSHR
SCHEMBL6413426 0.78 POLB (0.42) ALDH1A1KDM4ETSHRMAPK1MEN1
SCHEMBL6413379 0.74 TSHR (0.51) NPC1ALDH1A1KDM4ETSHRMEN1
SCHEMBL6416746 0.73 TSHR (0.51) NPC1ALDH1A1KDM4ETSHRL3MBTL1
SCHEMBL6413420 0.73 KMT2A (0.51) NPC1USP2ALDH1A1KDM4ETSHR
SCHEMBL6411648 0.71 HSD17B10 (0.51) NPC1ALDH1A1KDM4ETSHRMAPK1
SCHEMBL6410164 0.71 MAPT (0.56) NPC1ALDH1A1KDM4ETSHRMAPK1
SCHEMBL6410777 0.71 GAA (0.48) NPC1ALDH1A1KDM4ETSHRMAPK1
SCHEMBL6411977 0.71 NPC1 (0.44) NPC1USP2ALDH1A1RAB9AKDM4E
SCHEMBL6419719 0.71 HSD17B10 (0.50) NPC1ALDH1A1KDM4ETSHRMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050124614-A1 3,4-Dihydroisoquinolin-1-one derivatives as inducers of apoptosis AXYS PHARMACEUTICALS, INC. (US) 2005-06-09 US claimed
WO-2004004727-A1 3,4-DIHYDROISOQUINOLIN-1-ONE DERIVATIVES AS INDUCERS OF APOPTOSIS AXYS PHARMACEUTICALS, INC. (US) 2004-01-15 WO claimed
US-20050124614-A1 3,4-Dihydroisoquinolin-1-one derivatives as inducers of apoptosis AXYS PHARMACEUTICALS, INC. (US) 2005-06-09 US disclosed
WO-2004004727-A1 3,4-DIHYDROISOQUINOLIN-1-ONE DERIVATIVES AS INDUCERS OF APOPTOSIS AXYS PHARMACEUTICALS, INC. (US) 2004-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124614-A1 3,4-Dihydroisoquinolin-1-one derivatives as inducers of apoptosis CASP3, BAX, BAD NPC1 1504/4885USP2 2551/4885ALDH1A1 1368/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.